you, Kathy. Thank
to minutes, state North that Canada of please. I will health clinical review visibility current to and the upcoming And you and everyone afternoon available few efforts in our to DrugSorb today. activities the the hopefully our American necessary call Next will the providers. the make In for regulatory submissions U.S. on regulators ATR care next good provide slide, to into
a everyone to remind ATR like First, that DrugSorb breakthrough device. is I would
In separate ATR. breakthrough fact, FDA X designations has for DrugSorb the granted
applications.
We intended why. the removal or is explain that Eliquis the regulatory or for of patients anivaluants, an X Xarelto, DrugSorb surgery. market-leading the emergent removal ATR the and component or of urgent the of one rivaroxaban undergoing breakthrough having and me And let the strategy, important for for in same apixaban First, second status ticagrelor believe
designed breakthrough listed of program the process.
The this provide review by criteria required for unmet access both First, and specifically addressing the of breakthrough on up novel a devices designation is development phases speeding medical the large needs timely the device are to slide.
debilitating is or disease device conditions. that criteria for the first life-threatening treatment or or of The human diagnosis irreversibly provides effective more
in alternatives, must patients.
Since and the or breakthrough over is device or FDA it devices urology best designation will interest population XXXX, DrugSorb and the that technology, significant device the has it This urology intended submissions. that the advantages meet patients, cleared review the considerations: for granted cardiovascular are device are one our that no or brands criteria, a GI target of that to status second alternatives, and cardiovascular the because ATR FDA the be approved the and diagnostics. availabilities represents approved XX XXX GI relevant for least following For there cleared breakthrough at offers of existing
review breakthrough effectiveness. at meet ever for FDA Finally, and undergo submissions designation need the safety priority standards to and
slide, Next please.
AATS our webinar, to were stated STAR-T and the recently press STAR-T has transponder webinar the investigator, I were overview urge that STAR-T study cardiac practice Chan, Michael investigators principal to As Phil the CEO, listen adoption and Investor of all to by find link you Smoke. registry Michael can in principal also increasing in by results you, we you reviewed Dr. surgical Mack. by heard during you presentations presented X antithrombotic the European Key recent replay, Analyst Dr. an Opinion Dr. removal our Day that at from have our also and just and the Leader release, on of provided
the Let's results. now review the of STAR-T highlights
randomized First There were all, study. matrix. the the XXX of study subjects in
overall these or study the device, subjects. subjects receive isolated underwent did grafting, coronary XXX a and of surgery. bypass CABG X However, therefore, population comprises artery of not them, Among
subjects subjects cardiac investigative Canadian experiencing from a executed States sites. United While X% study the with under other well operators.
The than what deviation. approximately study split approximately protocol investigative The types enrollment X/X was X/X major and was XX% from came of of less sites of protocol
Finally, the and the by study trial. control endpoint to the arms of study met those were were in with monitoring the follow-up.
Reviewing there safety.
Overall, recommended complete continuation discontinuation adverse were reviews, device-related X device the events XX, primate reported. the overall XXX events that lost the concerns of X the unanticipated adverse and device-related patients XXX% primary events safety of In balanced X was entering and in study. the reviews as X -- that the no to the evidenced endpoint too reported, of XX around were after adverse and X safety of each was study between independent There board led patients occurred serious DSMB were adverse trial. There invoiced separate events device data safety population, one the
peribleeding We comprise Turning also that endpoints now and of by by the in from patients the the in events of drainage done the That postoperative assessed looking X via to collected universal efficacy. was study. of trial definition composite each the efficacy chested bleeding.
In bleeding. of exploratory executed addition, an assessment we major
had not the Luke the met. was endpoint previously, in primary As reported population composite overall
ratio both prespecified in the any who endpoint isolated following protocol among included did population, population CABG timing. remind so-called not you in patients moderate demonstrated a events, for the audience, major the any And win that let the isolated composite above effect investigation we of have treatment that The CABG for severe deviations the X the protocol However, me ratio suggests observed a and device. win X.XX. in bleeding
a cases with study that significant The the events to not X.XX, that demonstrated win p-value by composite the analysis ratio was of without of of be bleeding.
The number where on principal prespecified analysis events wanted simply evidence a included the of win identified a of they includes sensitivity the of bleeding severe a but endpoint which X.XX, blinded significant was results now included of ratio win X.XXX. at with the performance the is events the original X.XXX. a severe event analysis that were declared bleeding where only that of p-value with X.XXX.
Since that and in UDPB for any events included only the bleeding of allows review the clinical the However, therefore, endpoint were of has a significant the definition shown transfusions, moderate ensure bottom to simply the basis investigators sensitivity, in are clinical table composite also p-value of of or which transfusions, ratio
You that the to analysis severe sensitivity events events significant severe relating impacted the will all note be meaningful includes not clinically was bleeding. composite-only deem to events since would by
than noted placed for after analysis there the when chest to the major more that liter it that significant between X major versus was control the in or prevent UDPB of bleed that X.XXX.
The said, these to in rates the control to the or fleets analysis of one in drugs major definition were when for at total Finally, the UDPB were averted. X% drug in the X X control XX% we the arms, the for treated, X according major which X the arm. chested in suffered was exploratory there to in patients the And event patients there while X a XX to by to accounting events bar, bleeding treat, a total of surgery.
What translated leader exploratory events with with Otherwise major are this of according up bleeding in chested was that X chest over blood and trial drainage major ended either bar, DrugSorb X comes the p-value looked saw X. number to needed the there or those of That with that every the according in arm. events a of additional subjects drainage arm were
de emphasis novo of company is assurance population. probable Associates. and regulatory opinion there example, submissions. heavy the we intended available, please. slide quote reasonable the the data, on & Mark extensive device. novo devices with with shared the device. with us for controls, risk to To is experience a of of which provide With internal we strategy slide, preparation low safety to is moderate both our the J.D., DuVal, for have pathway the de of for puts data de and of President pathway working no STAR-T clinical "We device the this in submissions. formulate on of pathway."
More the specifically, experts, CEO top CytoSorbents approved Next Mr. other It device the development for Included and the regulatory experts availability DuVal special our the strategy is effectiveness, state, our for Based drug regulatory in but closely been of one The novo ATR de external and risk regulatory have appropriate novo senior the and data on from for have predicate has of benefit up drove the the worked direct to is leading
reviewed third based review health a in the days. we by recent reported proceeding XXX quarter the novo and a year. Importantly, cannabis times.
Accordingly, application are de FDA XX% priority this FDA received parallel times review novo finally, de stated devices, on novo with faster submissions applications will And analysis de be breakthrough as of for
post-COVID year. However, reviews averaging are in era, approximately such the X
please. slide, Next
that require was surgical will data large severe and indication increased and compare for an is our the and has be ticagrelor proposed the the observed lack recommend by we'll experts surgery; risk severity.
Based of the following be investigational care.
And facilitate risk in prepared review concludes an novo a U.S. for finally, my which FDA alternatives.
We proposed would over novo expected status ATR pathway. case, his be reduction like information; of ATR to in used STAR-T decision breakthrough perioperative on health that to highlighting an inform regulatory with potential the priority benefit X use the for providing this care unmet back of on FDA concluding DrugSorb de turn the device believe available for pathway submission. necessary with Breakthrough In use, submitting which, STAR-T, the bleeding widely the between profile de parallel, medical FDA CABG urgent intended I to remarks. CABG target of need months summarize, standard surgery safety population, patients pending that pathway, in information, QX agreement for And treatment.
DrugSorb is regulatory would bleeding the statements. to the it in information Phil submission And to but Canada, now for under FDA drug is to the as designation status So who does of XX to the FDA-approved also application,
